Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hypothesis :- - FMT is useful in reducing craving and return to heavy drinking in patients with alcohol related cirrhosis with active drinking, through modulation of gut microbiota and correction of dysbiosis
Aim and Objective -
- To assess the efficacy of FMT in decreasing lapse, relapses and maintaining alcohol abstinence in AUD in patients with cirrhosis
Study population:
- Patients with cirrhosis with recent alcohol use attending outpatient clinic at ILBS, New Delhi
Study design:
- Open label, parallel group, randomized, controlled study.
Study period:
- 1 year
Sample size with justification:
- Assuming that abstinence in Placebo group is 50% and we assume that there will be 40% absolute increase in FMT group (90%; Bajaj JS, Hepatology 2021) with alpha 5 and power of 80%, investigator need to enroll 48 cases, further assuming 10 % dropout rate it was decided to enroll 54 cases that is 27 in each group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FMT + SMT | Experimental | Therapy with Fecal microbiota transplantation with SMT (Baclofen + AUD counselling). - Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4. |
|
| Placebo + SMT | Active Comparator | Placebo therapy with SMT (Baclofen + AUD counselling) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FMT | Biological | - Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients achieving and maintaining alcohol abstinence at 4 weeks | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Gut microbiome alterations and relative abundance of gut associated bacteria. | Gut microbiome composition will be assessed by 16s Metagenomics | 12 weeks |
| Proportion of patients who got FMT at 12 weeks without liver related adverse effects compared to placebo. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dr Srajit Singh, MD | Contact | 01146300000 | srajitsinghparmar@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Liver & Biliary Sciences (ILBS) | Recruiting | New Delhi | National Capital Territory of Delhi | 110070 | India |
Not provided
| ID | Term |
|---|---|
| D008103 | Liver Cirrhosis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| SMT | Other | Baclofen + AUD counselling |
|
| Placebo | Other | Placebo identical to the FMT arm. |
|
| 12 weeks |
| Proportion of patients maintaining abstinence from alcohol at 3 & 6 months. | 3 and 6 months |
| Craving measures will be assessed based on pre-existing structured and validated questionnaires (Obsessive Compulsive Drinking Scale (OCDS) and Visual Analog Scale (VAS). | VAS ranges from 0 to 10, where 0 means no craving and 10 means most craving or strongest drive to consume alcohol, in our thesis) | 4,12 weeks and 6 months |
| Proportion of patients developing lapse and relapse at 4,12 weeks and 6 months. | 4,12 weeks and 6 months. |
| D013568 |
| Pathological Conditions, Signs and Symptoms |